Discoidin Domain Receptor 2 orchestrates melanoma resistance combining phenotype switching and proliferation-Reference-Cited by-同舟云学术

Discoidin Domain Receptor 2 orchestrates melanoma resistance combining phenotype switching and proliferation

Published:2022-03-23 Issue:18 Volume:41 Page:2571-2586
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Sala Margaux^ORCID,Allain Nathalie,Moreau Mélanie,Jabouille Arnaud^ORCID,Henriet Elodie,Abou-Hammoud Aya,Uguen Arnaud,Di-Tommaso Sylvaine,Dourthe Cyril,Raymond Anne-Aurélie,Dupuy Jean-William^ORCID,Gerard Emilie,Dugot-Senant Nathalie,Rousseau Benoit,Merlio Jean-Phillipe^ORCID,Pham-Ledart Anne,Vergier Béatrice,Tartare-Deckert Sophie,Moreau Violaine^ORCID,Saltel Frédéric^ORCID

Funder

Fondation de France

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

https://www.nature.com/articles/s41388-022-02266-1.pdf

Reference52 articles.

1. Ascierto PA, Kirkwood JM, Grob J-J, Simeone E, Grimaldi AM, Maio M, et al. The role of BRAF V600 mutation in melanoma. J Transl Med. 2012;10:85.

2. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949–54.

3. Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017;14:463–82.